Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33999716)

  • 1. Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer.
    Li Z; Yang L; Wang H; Binzel DW; Williams TM; Guo P
    Nucleic Acid Ther; 2021 Oct; 31(5):364-374. PubMed ID: 33999716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases.
    Jiang J; Lu Y; Chu J; Zhang X; Xu C; Liu S; Wan Z; Wang J; Zhang L; Liu K; Liu Z; Yang A; Ren X; Zhang R
    J Nanobiotechnology; 2024 Apr; 22(1):159. PubMed ID: 38589859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.
    Walker T; Nolte A; Steger V; Makowiecki C; Mustafi M; Friedel G; Schlensak C; Wendel HP
    Eur J Cardiothorac Surg; 2013 Mar; 43(3):628-33; discussion 633-4. PubMed ID: 23152437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975.
    Zhou D; Xia Z; Xie M; Gao Y; Yu Q; He B
    Hum Cell; 2021 Sep; 34(5):1478-1489. PubMed ID: 34244990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
    Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
    Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.
    Taverna S; Pucci M; Giallombardo M; Di Bella MA; Santarpia M; Reclusa P; Gil-Bazo I; Rolfo C; Alessandro R
    Sci Rep; 2017 Jun; 7(1):3170. PubMed ID: 28600504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression.
    Pi F; Binzel DW; Lee TJ; Li Z; Sun M; Rychahou P; Li H; Haque F; Wang S; Croce CM; Guo B; Evers BM; Guo P
    Nat Nanotechnol; 2018 Jan; 13(1):82-89. PubMed ID: 29230043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping.
    Zheng Z; Li Z; Xu C; Guo B; Guo P
    J Control Release; 2019 Oct; 311-312():43-49. PubMed ID: 31446085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
    Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
    Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.
    Xia J; Luo M; Dai L; Wang L; Wang L; Zhu J
    J Clin Lab Anal; 2021 May; 35(5):e23743. PubMed ID: 33682961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A targeted siRNA-loaded PDL1-exosome and functional evaluation against lung cancer.
    Lin X; Lin L; Wu J; Jiang W; Wu J; Yang J; Chen C
    Thorac Cancer; 2022 Jun; 13(11):1691-1702. PubMed ID: 35545838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
    Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
    J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.
    Day TF; Kallakury BVS; Ross JS; Voronel O; Vaidya S; Sheehan CE; Kasid UN
    Mol Cancer Res; 2019 May; 17(5):1207-1219. PubMed ID: 30647104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.